EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study

Study limitation reported by the research below: “The full text PDF content was not accessible — only the abstract and results excerpt were used. Methodological details (randomization stratification, blinding, statistical analysis plan) could not be independently verified.”